ANDA 78282, held by Rubicon Research. Levofloxacin.
As of Nov 16, 2026, ANDA 78282 (Levofloxacin), held by Rubicon Research, was first approved by FDA on Dec 20, 2010, with 1 approved supplement and 0 published complete response letters.
Levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Gram-positive bacteria Corynebacterium species * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Streptococcus (Groups C/F) Streptococcus (Group G) Viridans group streptococci* Gram-negative bacteria Acinetobacter lwoffii * Haemophilus influenzae Serratia marcescens* *Efficacy for this organism was studied in fewer than 10 infections
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin0.5% · solution/drops;ophthalmic | Levofloxacin | Rx |
| May 5, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 20, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters